Next steps in clinical translation First-in-human safety trials (phase I) are essential: to assess dose tolerability, pharmacokinetics, biodistribution, peptide half-life, clearance, immunogenicity
The frequency will be as prescribed, often once a week or as directed
These products are not subject to the same pharmaceutical manufacturing standards, sterility testing, or third-party verification that a licensed 503A compounding pharmacy must meet
Prioritizing sleep quality and duration enhances the regenerative environment in which peptides operate
Additionally, it displays anti-inflammatory properties, which can aid in reducing pain and swelling associated with these conditions
Stocchetti N, Zanier ER